Video

VIDEO: Rho kinase inhibitors beneficial as adjunctive glaucoma therapy

NEW YORK At the American Glaucoma Society annual meeting, Savak "Sev" Teymoorian, MD, MBA discusses the benefits of Rho-kinase inhibitors as adjunctive glaucoma therapy. Compared with prostaglandin, Rho kinase inhibitors need only once-daily treatment and are associated with no systemic side effects.

NEW YORK At the American Glaucoma Society annual meeting, Savak "Sev" Teymoorian, MD, MBA discusses the benefits of Rho-kinase inhibitors as adjunctive glaucoma therapy. Compared with prostaglandin, Rho kinase inhibitors need only once-daily treatment and are associated with no systemic side effects.

    See more from American Glaucoma Society Meeting